<p>The U.S. Food and Drug Administration has called for an assessment of potential neurocognitive side effects of an experimental cholesterol drug being developed by Regeneron and Sanofi, Sanofi said...
An FDA advisory committee has voted in favor of changing the labeling language warning of possible heart issues while taking NSAIDs after reviewing, and refuting, a new study.